SHR-A1921

Phase 3Small molecule

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

SHR-A1921 is one of 196 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

195

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerRecruiting

Advanced Breast CancerRecruiting

Ovarian CancerRecruiting

Salivary Gland CarcinomaActive, not recruiting

Patients With Advanced Solid TumorsActive, not recruiting

Advanced NSCLCNot yet recruiting

Breast CancerPhase 2

Recruiting

Advanced Breast CancerPhase 2

Recruiting

Ovarian CancerPhase 3

Recruiting

Salivary Gland CarcinomaPhase 2

Active, not recruiting

Patients With Advanced Solid TumorsPhase 2

Active, not recruiting

Advanced NSCLCPhase 2

Not yet recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

SHR-A1921

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

3 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Breast Cancer

NCT05594095

Phase 2Active, not recruiting

Salivary Gland Carcinoma

NCT05924256

Phase 3Recruiting

Ovarian Cancer

NCT06394492

Q2 2027

Phase 2Not yet recruiting

Advanced NSCLC

NCT06465238

Q3 2027

Phase 2Recruiting

Advanced Breast Cancer

NCT06649331

Q4 2027

Phase 2Recruiting

Advanced Breast Cancer

NCT06433609

Clinical

Trials by Indication[1]

Breast Cancer3 trials

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06470672·32 enrolled

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting·FFudan University·Phase 2·NCT05594095·620 enrolled

Advanced Breast Cancer2 trials

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Phase 2 Trial

Recruiting·FFudan University·Phase 2·NCT06649331·160 enrolled

A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Recruiting·BBeijing GoBroad Hospital·Phase 2·NCT06433609·113 enrolled

Patients With Advanced Solid Tumors1 trial

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Active, not recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1/2·NCT05765032·220 enrolled

Advanced Solid Tumours1 trial

A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours

Unknown status· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1·NCT05154604·156 enrolled

Ovarian Cancer1 trial

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06394492·440 enrolled

2 more indications

Salivary Gland Carcinoma1 trial

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Active, not recruiting·FFudan University·Phase 2·NCT05924256·88 enrolled

Advanced NSCLC1 trial

Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT06465238·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for SHR-A1921. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-A1921 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-A1921. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Suncadia Biopharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

SHR-A1921

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Breast Cancer3 trials

Advanced Breast Cancer2 trials

Patients With Advanced Solid Tumors1 trial

Advanced Solid Tumours1 trial

Ovarian Cancer1 trial

Salivary Gland Carcinoma1 trial

Advanced NSCLC1 trial

References

Drug Info

Quick Facts

Related News